<?xml version='1.0' encoding='utf-8'?>
<document id="19581505"><sentence text="Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema." /><sentence text="Dipeptidyl peptidase-IV (DPP-IV) inhibitors decrease degradation of the incretins" /><sentence text=" DPP-IV inhibitors also decrease degradation of peptides, such as substance P, that may be involved in the pathogenesis of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema"><entity charOffset="123-134" id="DDI-PubMed.19581505.s3.e0" text="angiotensin" /></sentence><sentence text=" This study tested the hypothesis that DPP-IV inhibition affects risk of clinical angioedema, by comparing the incidence of angioedema in patients treated with the DPP-IV inhibitor vildagliptin versus those treated with comparator in Phase III randomized clinical trials" /><sentence text=" Prospectively defined angioedema-related events were adjudicated in a blinded fashion by an internal medicine adjudication committee and expert reviewer" /><sentence text=" Concurrent ACE inhibitor or angiotensin receptor blocker exposure was ascertained from case report forms"><entity charOffset="29-40" id="DDI-PubMed.19581505.s6.e0" text="angiotensin" /></sentence><sentence text=" Study drug exposure was ascertained from unblinded data from phase III studies" /><sentence text=" Odds ratios and 95% confidence intervals comparing angioedema risk in vildagliptin-treated and comparator-treated patients were calculated for the overall population and for patients taking ACE inhibitors or angiotensin receptor blockers, using both an analysis of pooled data and a meta-analysis (Peto method)"><entity charOffset="71-83" id="DDI-PubMed.19581505.s8.e0" text="vildagliptin" /></sentence><sentence text=" Overall, there was no association between vildagliptin use and angioedema"><entity charOffset="43-55" id="DDI-PubMed.19581505.s9.e0" text="vildagliptin" /></sentence><sentence text=" Among individuals taking an ACE inhibitor, however, vildagliptin use was associated with an increased risk of angioedema (14 confirmed cases among 2754 vildagliptin users versus 1 case among 1819 comparator users: odds ratio 4"><entity charOffset="53-65" id="DDI-PubMed.19581505.s10.e0" text="vildagliptin" /><entity charOffset="153-165" id="DDI-PubMed.19581505.s10.e1" text="vildagliptin" /><pair ddi="false" e1="DDI-PubMed.19581505.s10.e0" e2="DDI-PubMed.19581505.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19581505.s10.e0" e2="DDI-PubMed.19581505.s10.e1" /></sentence><sentence text="57 [95% confidence interval 1" /><sentence text="57 to 13" /><sentence text="28]) in the meta-analysis" /><sentence text=" Vildagliptin use may be associated with increased risk of angioedema among patients taking ACE inhibitors, although absolute risk is small"><entity charOffset="1-13" id="DDI-PubMed.19581505.s14.e0" text="Vildagliptin" /></sentence><sentence text=" Physicians confronted with angioedema in a patient taking an ACE inhibitor and DPP-IV inhibitor should consider this possible drug-drug interaction" /><sentence text="" /></document>